

Supplementary Materials for

Sortilin gates neurotensin and BDNF signaling to control peripheral neuropathic pain

Mette Richner, Lone T. Pallesen, Maj Ulrichsen, Ebbe T. Poulsen, Thomas H. Holm, Hande Login, Annie Castonguay, Louis-Etienne Lorenzo, Nádia P. Gonçalves, Olav M. Andersen, Karin Lykke-Hartmann, Jan J. Enghild, Lars C. B. Rønn, Ibrahim J. Malik, Yves De Koninck, Ole J. Bjerrum, Christian B. Vægter*, Anders Nykjær

*Corresponding author. Email: cv@biomed.au.dk

Published 19 June 2019, *Sci. Adv.* **5**, eaav9946 (2019)

DOI: 10.1126/sciadv.aav9946

This PDF file includes:

- Fig. S1. Injury-induced microglia reactivity in WT and *Sort1*^{-/-} lumbar spinal cord.
- Fig. S2. Neurochemical markers remain intact in sortilin-deficient mice.
- Fig. S3. Direct KCC2 inhibition induces pain hypersensitivity.
- Fig. S4. Subcellular localization of TrkB is unchanged in SDH of sortilin-deficient mice.
- Fig. S5. mRNA and protein levels of neurotensin and NTSR2 are unchanged in sortilin-deficient mice.
- Fig. S6. Sortilin allows direct manipulation of the pain response to neuronal injury.
- Fig. S7. *Hum-sortilin-KI* mouse model.




Fig. S1. Injury-induced microglia reactivity in WT and *Sort1*^{-/-} lumbar spinal cord. Representative images of immunofluorescence labelling of Iba1 (green, microglia marker) in spinal L3-L5 sections of WT and *Sort1*^{-/-} mice 0 and 2 days post SNI (injury on right side); scale bar = 500 μ m, n = 3.




Fig. S2. Neurochemical markers remain intact in sortilin-deficient mice. GABA, glycine and glutamate in spinal L3-L5 sections of naïve WT and *Sort1*^{-/-} mice (n = 3, unpaired t-test, ns = not significant, means ± SEM).



A**B**

Fig. S3. Direct KCC2 inhibition induces pain hypersensitivity. (A) Measurements of KCC2 activity in reverse mode by K^+ -driven uptake of Cl^- in superficial dorsal horn neurons of lumbar spinal cord, as lifetime (LT) change in nanoseconds per second (ns/s). 56-60 cells in 9-10 lumbar spinal cord slices from 4 animals were analyzed for each genotype ($n = 9-10$, t-test, ns = not significant, means \pm SEM). (B) PWT to tactile stimuli of naïve WT and *Sort1*^{-/-} mice with i.t. injection of VU0463271 (* $P < 0.03$, ** $P < 0.007$ versus -1 d of the same mouse, $n = 3$, RM two-way ANOVA with post hoc Sidak's test ($F(1,4) = 0.1266$, $P = 0.7400$), means \pm SEM).



A**B**

Fig. S4. Subcellular localization of TrkB is unchanged in SDH of sortilin-deficient mice. WB of subcellular fractionation of 8 pooled SDH of spinal L3-L5 from naïve WT and *Sort1*^{-/-} mice (A) TrkB, PSD95 and synaptophysin in fractions P1 to S3, n = 1. (B) TrkB, PSD95 and synaptophysin in fractions SVP to SPD2.




A**B****C**

Fig. S5. mRNA and protein levels of neurotensin and NTSR2 are unchanged in sortilin-deficient mice. (A) qPCR of neurotensin mRNA levels (delta-CT) in SDH L3-L5 of WT and *Sort1*^{-/-} mice 6 d post SNI (n = 3, one-way ANOVA with *post hoc* Tukey's test, ns = not significant, means ± SEM). (B) MS of neurotensin levels in SDH L3-L5 of WT and *Sort1*^{-/-} mice 6 d post SNI (n = 6, one-way ANOVA with *post hoc* Tukey's test, means ± SEM). (C) NTSR2 protein levels (by WB) in SDH L3-L5 of WT and *Sort1*^{-/-} mice (n = 3, one-way ANOVA with *post hoc* Tukey's test, means ± SEM).




Fig. S6. Sortilin allows direct manipulation of the pain response to neuronal injury. (A) Upon neuronal injury, released BDNF activates the central BDNF-TrkB pain inducing pathway leading to KCC2 downregulation. In WT mice, sortilin (possibly both membrane-bound and soluble forms) scavenges neurotensin thereby preventing neurotensin from activating NTSR2, permitting the BDNF-TrkB pain pathway to induce KCC2 downregulation and neuropathic pain (red arrows). (B) In absence of or upon inhibition of sortilin (by antibodies or the small-molecule AF38469), neurotensin activates NTSR2, which inhibits BDNF-TrkB pathway induced KCC2 downregulation and pain development (red arrow). I.t. injection of soluble sortilin to injured *Sort1*^{-/-} mice (not shown) restores the neurotensin scavenging capacity allowing pain development.



A**B**

Fig. S7. *Hum-sortilin-KI* mouse model. C57BL/6J mice expressing the human *SORT1* gene under the control of the endogenous mouse *Sort1* promoter (*hum-sortilin-KI*). (A) The coding region in mouse exon 1 was replaced with a human *SORT1* cDNA, see Methods section for details. (B) Protein expression was confirmed by Western blotting of nerve tissue